Debanjana Chatterjee
Stock Analyst at Jones Trading
(3.74)
# 759
Out of 5,005 analysts
11
Total ratings
80%
Success rate
27.74%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Debanjana Chatterjee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SION Sionna Therapeutics | Initiates: Buy | $46 | $30.01 | +53.28% | 1 | Sep 8, 2025 | |
| TBPH Theravance Biopharma | Initiates: Buy | $24 | $14.41 | +66.55% | 1 | Jun 17, 2025 | |
| SGMT Sagimet Biosciences | Maintains: Buy | $15 → $27 | $7.29 | +270.37% | 2 | Jun 6, 2025 | |
| TVRD Tvardi Therapeutics | Initiates: Buy | $39 | $40.23 | -3.06% | 1 | Apr 28, 2025 | |
| KALV KalVista Pharmaceuticals | Maintains: Buy | $30 | $11.85 | +153.16% | 2 | Mar 26, 2025 | |
| CTNM Contineum Therapeutics | Initiates: Buy | $23 | $11.35 | +102.64% | 1 | Mar 13, 2025 | |
| SYRE Spyre Therapeutics | Initiates: Hold | n/a | $15.89 | - | 1 | Dec 11, 2024 | |
| PHVS Pharvaris | Initiates: Buy | $46 | $23.39 | +96.67% | 1 | Sep 19, 2024 | |
| NTLA Intellia Therapeutics | Initiates: Buy | $41 | $19.96 | +105.41% | 1 | Sep 17, 2024 |
Sionna Therapeutics
Sep 8, 2025
Initiates: Buy
Price Target: $46
Current: $30.01
Upside: +53.28%
Theravance Biopharma
Jun 17, 2025
Initiates: Buy
Price Target: $24
Current: $14.41
Upside: +66.55%
Sagimet Biosciences
Jun 6, 2025
Maintains: Buy
Price Target: $15 → $27
Current: $7.29
Upside: +270.37%
Tvardi Therapeutics
Apr 28, 2025
Initiates: Buy
Price Target: $39
Current: $40.23
Upside: -3.06%
KalVista Pharmaceuticals
Mar 26, 2025
Maintains: Buy
Price Target: $30
Current: $11.85
Upside: +153.16%
Contineum Therapeutics
Mar 13, 2025
Initiates: Buy
Price Target: $23
Current: $11.35
Upside: +102.64%
Spyre Therapeutics
Dec 11, 2024
Initiates: Hold
Price Target: n/a
Current: $15.89
Upside: -
Pharvaris
Sep 19, 2024
Initiates: Buy
Price Target: $46
Current: $23.39
Upside: +96.67%
Intellia Therapeutics
Sep 17, 2024
Initiates: Buy
Price Target: $41
Current: $19.96
Upside: +105.41%